Skip to Content

Posts tagged with "Cancer"

  • Cancer

    Genetic Optimism

    he genetic news of the day, subject of good-sized headlines in the Wall St. Journal and elsewhere, is an upcoming paper in PNAS on a candidate cancer gene called DBC2. Some of these abbreviations are pretty recondite, but not this one – it stands for “Deleted in Breast Cancer,” which is pretty tame by the… Read More
  • Cancer

    The Wall Street Journal versus the FDA

    Here we are again. Back in February (see the Feb. 27th post), the FDA asked for more data for Imclone’s cancer therapy, Erbitux, saying the existing studies were not sufficient to approve the drug. The Wall Street Journal’s editorial page threw a memorable fit about what they saw as the FDA’s intransigence (to which piece… Read More
  • Cancer

    Consequences of Aneuploidy

    Man, with headlines like that, I can’t think of why I’m not pulling in thousands of hits a day. Anyway, I wanted to follow up on yesterday’s posting by emphasizing that aneuploidy hasn’t been ignored for all these years. It’s just that the chicken-and-egg question about its role in cancer is heating up. For example… Read More
  • Cancer

    Aneuploidy, or What’re A Few Chromosomes, More or Less?

    My recent posts about the Ames test (see July 29 and July 30) went into some detail about its use for estimating the mutagenicity of a compound. And mutagenicity is of course a bad thing, because increased DNA damage is generally held to be a factor in carcinogenesis. But just how that works is the… Read More
  • Cancer

    HER-1 And HER-2, Too

    AstraZeneca’s revelation yesterday was quite disturbing. Their experimental cancer therapy (Iressa) doesn’t seem to offer any added benefits when given in chemotherapy combinations, at least in non-small cell lung cancer. That’s a type of tumor that the approach really should have worked in, and one that the compound had shown som… Read More
  • Cancer

    Save Your Tears

    Having unloaded on the Weekly Standardlast week, I now find myself taking aim at the Wall Street Journal. Pretty soon, I’m going to be in the pundit equivalent of Albania (as was,) having ditched my every natural ally. But it has to be done. The Journal has an editorial today on the Imclone situation – Read More
  • Cancer

    A Few Words

    I see that some of my comments have spread to investors in Entremed, so let me take a few paragraphs to mention some points. I should write these up in a combination FAQ / disclaimer to deal with these situations. First off, as it says on the top of the page, I don’t speak for… Read More
  • Cancer

    Did He Say What They Thought He Said?

    I’ve received some mail pointing out that James Watson denied the “cure cancer in two years” quote which appeared in the 1998 Times article. I was aware of those denials, but (since you have to make a judgment call on these things,) I believe that he probably did say it. Why? First of all, because… Read More
  • Cancer

    Now Is the Peptide of Our Discontent

    Mickey Kaus, in his link to yesterday’s post, mentioned that the company I work for seems down on peptides as drugs, and asked his readers to keep that in mind when they read my opinion on endostatin. All I can say is, it isn’t just me (or my company.) You won’t find much of anyone… Read More
  • Cancer

    Hype and Glory

    Over at the new home of Kausfiles, Mickey Kaus wondered on Monday about all the news coming out of the ASCO (American Society for Clinical Oncology) meeting. Does it show that the hype in the famous 1998 NY Times front-page story on Judah Folkman and his cancer therapy was actually justified? Does the world owe… Read More
...373839